anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a Chinese and western compound medicine (Xishuyuan) for treating upper respiratory tract infection, which is prepared by mixing Chinese medicine components and western medicine components. The traditional Chinese medicine components comprise radix curcumae, radix rehmanniae recen, herba pogostemonis, lucid ganoderma, fructus aurantii and poria cocos, and the western medicine component is cefuroxime tablets. The contents of the components are as follows: 15 g of traditional Chinese medicine curcuma aromatica, 10 g of dried rehmannia root, 10 g of patchouli, 15 g of lucid ganoderma, 5 g of bitter orange and 5 g of tuckahoe, and 8 tablets of western medicine cefuroxime, wherein each tablet is 0.25 g; forming a prescription. The invention combines modern Chinese and western medicine, and the successfully developed compound medicine is used for treating respiratory tract bacterial infection and viral infection. Can dissolve phlegm, eliminate bacteria or viruses of phlegm and pus generated in human respiratory tract, reduce nasal obstruction, sneeze, throat abscess, pneumonia and cough, and effectively suppress the occurrence probability of headache and fever. Has little side effect, takes effect in 30 minutes and does not hurt the liver, the brain and the kidney.
This project plans to enroll 40 patients receiving nanoknife treatment, our center enrolls 20 patients, and the other two centers will enroll 10 patients each. The number of patients expected to participate in the study is 240.
The importance of neuroinflammation during the ischemic stroke has been extensively studied. The role of CD4+CD25+ regulatory T (Treg) cells during the recovery phase have shown infarct size reduction and functional improvement, possibly through the mitigation of inflammatory immune responses. We aimed to investigate the molecular factors involved in microglia-Treg cell communication that result in Treg trafficking. First, we observed the migration patterns of CD8+ (cytotoxic) T cells and Treg cells and then searched for chemokines released by activated microglia in an oxygen-glucose deprivation (OGD) model. The transwell migration assay showed increased migration into OGD media for both cell types, in agreement with the increase in chemokines involved in immune cell trafficking from the mouse chemokine profiling array. MSCV retrovirus was transduced to overexpress CCR4 in Treg cells. CCR4-overexpressed Treg cells were injected into the mouse transient middle cerebral artery occlusion (tMCAO) model to evaluate the therapeutic potential via the tetrazolium chloride (TTC) assay and behavioral tests. A general improvement in the prognosis of animals after tMCAO was observed. Our results suggest the increased mobility of CCR4-overexpressed Treg cells in response to microglia-derived chemokines in vitro and the therapeutic potential of Treg cells with increased mobility in cellular therapy.
Cohort 1 is a a control group matched 1:5 to the exposed group on sex and age. This group i randomly assigned via Statistics Denmark and does not have a diagnosis of back pain in the time period 2008-2013. They do however have another diseases registered in the Danish Patient Registry, which only contains information on patients having had contacts with the hospital sector i Denmark. Used for study 1.
BACKGROUND: Although it has been established that elevated blood pressure and its variability worsen outcomes in spontaneous intracerebral hemorrhage, antihypertensives use during the acute phase still lacks robust evidence. A blood pressure-lowering regimen using remifentanil and dexmedetomidine might be a reasonable therapeutic option given their analgesic and antisympathetic effects. The objective of this superiority trial was to validate the efficacy and safety of this blood pressure-lowering strategy that uses remifentanil and dexmedetomidine in patients with acute intracerebral hemorrhage.
METHODS: In this multicenter, prospective, single-blinded, superiority randomized controlled trial, patients with intracerebral hemorrhage and systolic blood pressure (SBP) 150 mmHg or greater were randomly allocated to the intervention group (a preset protocol with a standard guideline management using remifentanil and dexmedetomidine) or the control group (standard guideline-based management) to receive blood pressure-lowering treatment. The primary outcome was the SBP control rate (less than 140 mmHg) at 1 h posttreatment initiation. Secondary outcomes included blood pressure variability, neurologic function, and clinical outcomes.
RESULTS: A total of 338 patients were allocated to the intervention (n = 167) or control group (n = 171). The SBP control rate at 1 h posttreatment initiation in the intervention group was higher than that in controls (101 of 161, 62.7% vs. 66 of 166, 39.8%; difference, 23.2%; 95% CI, 12.4 to 34.1%; P < 0.001). Analysis of secondary outcomes indicated that patients in the intervention group could effectively reduce agitation while achieving lighter sedation, but no improvement in clinical outcomes was observed. Regarding safety, the incidence of bradycardia and respiratory depression was higher in the intervention group.
CONCLUSIONS: Among intracerebral hemorrhage patients with a SBP 150 mmHg or greater, a preset protocol using a remifentanil and dexmedetomidine-based standard guideline management significantly increased the SBP control rate at 1 h posttreatment compared with the standard guideline-based management.
Synthetic resin moulding powders for the production of dental protheses or artificial limbs are made by cutting up or grinding highly polymerised block polymers or pearl polymers.  The pearl polymers which contain bubbles of air and water are pre-treated by racking and then comminuted in a ball mill until no whole pearls are left.  Block polymers produced by polymerisation of monomeric compounds without dispersing media or diluents are cut into shreds and comminuted in a mill.  When high accuracy is required in the moulded product such as optical lenses and dental protheses the comminuted polymers e.g. methylmethacrylates, are mixed with monomeric polymerisable compounds.  The block polymers may be produced by heating monomers with catalysts.  The polymers used may be mixed polymers of vinyl chlorides and vinyl acetates.
This study aimed to compare the systemic and local metabolic responses during a 5-min trunk extension exercise in individuals with chronic low back pain (CLBP) and in healthy individuals. Thirteen active participants with CLBP paired with 13 healthy participants performed a standardised 5-min trunk extension exercise on an isokinetic dynamometer set in continuous passive motion mode. During exercise, we used near-infrared spectroscopy to measure tissue oxygenation (TOI) and total haemoglobin-myoglobin (THb). We used a gas exchange analyser to measure breath-by-breath oxygen consumption (V̇O2) and carbon dioxide produced (V̇CO2). We also calculated mechanical efficiency. We assessed the intensity of low back pain sensation before and after exercise by using a visual analogue scale. In participants with CLBP, low back pain increased following exercise (+ 1.5 units; p < 0.001) and THb decreased during exercise (- 4.0 units; p = 0.043). Paraspinal muscle oxygenation (65.0 and 71.0%, respectively; p = 0.009) and mechanical efficiency (4.7 and 5.3%, respectively; p = 0.034) were both lower in participants with CLBP compared with healthy participants. The increase in pain sensation was related to the decrease in tissue oxygenation (R2 = - 0.420; p = 0.036). Decreases in total haemoglobin-myoglobin and mechanical efficiency could involve fatigability in exercise-soliciting paraspinal muscles and, therefore, exacerbate inabilities in daily life. Given the positive correlation between tissue oxygenation and exercise-induced pain exacerbation, muscle oxygenation may be related to persisting and crippling low back pain.
PROBLEM TO BE SOLVED: To obtain a cleansing composition to which silicone oil is stably formulated, moreover, excellent in cleaning properties and shape retention, easy to handle and giving good sense of use by adding a combination of a specific phosphate salt and a specific oil to a system containing silicone oil. SOLUTION: Silicone oil is combined with dialkyl phosphate salt, hydrocarbon oil or ester oil. As a dialkyl phosphate salt, is preferably cited a compound of the formula (R<1> and R<2> are each a hydrocarbon, M<n+> is a n-valent metallic ion; n is 2, 3), for example, calcium diisooctadecyl phosphate. The amount of the dialkyl phosphate salt is preferably 0.1-30wt.%, particularly 3-8wt.%. The hydrocarbon oil is preferably fluid paraffin, while the ester oil is isononyl isononanoate, isopropyl palmitate or the like. Their formulation is preferably 10-98wt.%, particularly 40-80wt.%. The silicone oil is a linear dimethylpolysiloxane of a low degree of polymerization in an amount of about 10-60wt.% based on the whole composition.
Following abrupt cessation of therapy with certain beta-blocking agents in patients with coronary artery disease, exacerbations of angina pectoris and, in some cases, myocardial infarction have been reported. Therefore, such patients should be cautioned against interruption of therapy without the physician's advice. Even in the absence of overt angina pectoris, when discontinuation of atenolol and chlorthalidone tablets is planned, the patient should be carefully observed and should be advised to limit physical activity to a minimum. Atenolol and chlorthalidone tablets should be reinstated if withdrawal symptoms occur. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue atenolol and chlorthalidone tablets therapy abruptly even in patients treated only for hypertension.

Concomitant Use of Calcium Channel Blockers 

Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. Patients with pre-existing conduction abnormalities or left ventricular dysfunction are particularly susceptible (See PRECAUTIONS).
Early Hearing Detection and Intervention (EHDI) programmes are recognised as the standard of care for newborns and infants presenting with hearing impairment, globally. However, widespread implementation of these programmes is far from being realised and faces numerous challenges within the South African context. The United Nations' sustainable development goal 3.8 and South Africa's national development plan seek to achieve equitable access to healthcare service, including EHDI. However, healthcare access is a complex concept which encompasses the dimensions: availability, affordability, acceptability and accommodation in healthcare. South Africa has made great progress towards universal implementation of EHDI programmes. Despite this progress, availability and affordability of these programmes are limited and their acceptability has received limited research focus in this context. Furthermore, accommodation of caregivers, as co-drivers of EHDI programmes and ensuring that EHDI programmes are linguistically and culturally congruent have also been overlooked within the South African context.Contribution: Increased robust efforts in improving access through availability and affordability of EHDI programmes are warranted in South Africa. However, improving access to these programmes through availability and affordability initiatives alone will not result in a pragmatic improvement in their accessibility. Acceptability of these programmes and accommodations such as involving caregivers and family members of children with hearing impairment as equal partners in EHDI programmes and being cognisant of their linguistic and cultural needs must be considered.
FIELD: medicine, biotechnology. SUBSTANCE: invention relates to development of method for preparing neutral lipids exhibiting high activity and sufficient purity degree for intravenous administration and composition based on thereof for oral, intravenous and intraarterial administration. Neutral lipids isolated from Job's tears grains are triglycerides, diglycerides, monoglycerids and fatty acid alkyl ester. Method of preparing involves an extraction of Job's tears grains with an organic solvent, alkaline saponification, neutralization of obtained emulsion with acetone, deemulsification with acetone and purification of acetone fraction by extraction of the end product with an organic solvent. A pharmaceutical composition consists of neutral lipids at amount 2.5-25 g and pharmaceutically acceptable additions and shows antitumor and immunostimulating effects. EFFECT: simplified method, decreased cost and toxicity of chemotherapeutic effect, safety of composition. 9 cl, 9 ex, 5 dwg
A coated supermolecule salicylic acid composition, a preparation method and an application thereof relate to the components of raw materials of cosmetics and personal washing and caring products and the improvement of the preparation method, in particular to the improvement of the supermolecule salicylic acid composition. The supermolecule-wrapped salicylic acid composition is prepared from the following components in parts by weight: 5-60 parts of salicylic acid, 5-50 parts of amino acid, 1-30 parts of polysaccharide substance and 1-40 parts of cyclodextrin. The composition has good water solubility and low irritation, particularly meets the later application of cosmetics and personal washing and protecting products, and has the advantages of high bioavailability, difficult precipitation and crystallization of salicylic acid of later products and the like. The invention uses cyclodextrin to wrap the salicylic acid supermolecule, uses the characteristic that cyclodextrin molecules have ring cavity molecules, and the main molecule has a larger cavity structure, so that guest molecules-supermolecule salicylic acid can be contained in the main molecule to form a molecular capsule. By the molecular encapsulation, the supramolecular salicylic acid has the advantages of better water-soluble dispersibility, very low irritation, higher bioavailability and the like. Thereby effectively improving the inhibition rate of the salicylic acid on harmful bacteria such as acne bacillus, malassezia and the like in the formulas of shampoo, skin care products and the like, and improving the effect of the salicylic acid on resisting the problems of acne, dandruff, excessive secretion of grease and the like.
BACKGROUND: Despite respiratory infections being a leading cause of hospitalization in children with tracheostomy tubes, there are no published guidelines for their diagnosis and management. This study aims to outline the clinical, laboratory and microbiological aspects of pneumonia in these children, along with the antibiotics used and outcomes. Additionally, it seeks to determine pneumonia incidence and associated risk factors.
METHODS: We conducted a retrospective study using the medical records of tracheostomized children at La Paz University Hospital in Madrid from 2010 to 2021.
RESULTS: Thirty-three pneumonia cases were observed in 25 tracheostomized children. Pseudomonas aeruginosa was the predominant bacterium (52%), followed by Escherichia coli , Staphylococcus aureus and Serratia marcescens . The same microorganism isolated in the tracheal aspirate culture during pneumonia was previously isolated in 83% of cases that had a similar culture, with some growth obtained within 7-30 days prior. Multiplex respiratory PCR detected respiratory viruses in 73% of cases tested. Antibiotic treatment was administered in all cases except 1, mostly intravenously (81%), with piperacillin/tazobactam and meropenem being commonly used. Only 1 of the described episodes had a fatal outcome.
CONCLUSIONS: It is advisable to include coverage for P. aeruginosa , E. coli , S. aureus , and S. marcescens in the empirical antibiotic treatment for pneumonia in tracheostomized children, along with the microorganisms identified in tracheal cultures obtained within 7-30 days prior, if available. A positive PCR for respiratory viruses is often discovered in bacterial pneumonia in tracheostomized children.
* Patients selection, inclusion and procedure: All successive patients admitted to the medical or surgical ICU, and intubated by the orotracheal route for \>6 days, will be prospectively enrolled when extubation will be decided. Patients with previous swallowing disorders, ENT surgery or chronic persistent vegetative status will not be included. All patients will have to fulfill the usual criteria for extubation. Then, before extubation, the different components of swallowing functions will be evaluated by the trained physiotherapist, using a bedside pre-extubation scale based on 3 tests: assessment of 1)- cervical, oral, labial and lingual motricity; 2)- the gag reflex; and 3)- swallowing. After extubation, the ability to cough and swallow, secretion volume, and the need for suctioning will be evaluated immediately, then at 24, 48 and 72 hours.
* Expected results : to validate a scale previously devised called " physiotherapist evaluation of the swallowing function and oropharyngeal motricity before extubation" by the mean of a multicentric study. In our hypothesis the clinical parameters studied could be predictive of extubation failure. Then, this evaluation could help the medical decision in the choice of the good time for extubation. The final objective is to lower the mortality related to extubation failure.
Group A will consist of six subjects receiving a single dose of either a low dose of Aes-103 (300 mg) or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second, higher dose of Aes-103 (1,000 mg), and subjects initially randomized to placebo will receive a second dose of placebo without food.
A formulation with a pharmaceutical agent solubilized in a propellant can be administered buccally or into the lungs using a metered dose spray applicator.  The pharmaceutical agent is dispensed from a pressurized container containing a stable solubilized mixture of propellant which is liquid under pressure and an intermediate formulation.  The intermediate formulation comprises the proteinic pharmaceutical agent, water, first ingredient, second ingredient and at least one third ingredient.  The first ingredient is glycerin and/or polyglycerin in an amount of from 1-50 wt./wt.% of the intermediate formulation.  The second ingredient is phenol and/or methyl phenol in an amount of from 1-20 wt./wt.% of the intermediate formulation.  Each third ingredient is selected from the group consisting of alkali metal C8 to C22 alkyl sulphate, polidocanol C6 to C40 alkyl ethers, trihydroxy sodium oxo-cholanyl glycines, polyoxyethylene sorbitanethers, alkyl-aryl polyether alcohols, hyaluronic acid and pharmaceutically suitable salts thereof, monoolein, triolein, lysine, polylysine, oleic acid, linoleic acid, linolenic acid, monooleates and laurates, glycolic acid, lactic acid, chenodeoxycholate, deoxycholate, chamomile extract, cucumber extract, borage oil and evening of primrose oil and mixtures thereof, in an amount of from 1-50 wt./wt.% of the intermediate formulation.  The total concentration of first, second and third ingredients is less than 90 wt./wt.% of the intermediate formulation.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: method of obtaining dry diketopiperaxine powder includes obtaining diketopiperazine solution, stage of diketopiperazine-containing particles formation and removal of solvent by drying by means of dispersion. Method can include additional stage of loading diketopiperazine particles with active agent, which represents peptide or protein, preferably, insulin. Diketopiperazine preferably is fumaryldiketopiperazine. Diketopiperazine particles, obtained by invention method, possess improved aerodynamic characteristics, active agent, in particular insulin, is more stable and is delivered in more efficient way in comparison with composition of diketopiperazine-insulin, dried by means of sublimation. ^ EFFECT: dry powders are used as compositions of pharmaceutical preparations for delivery in pulmonary way. ^ 16 cl, 10 dwg, 5 tbl, 8 ex
Participants randomized to the resistance training (RT) group will receive an in-person and telephone-based intervention to promote home-based resistance training. The exercise intervention will begin by the 3rd adjuvant chemotherapy visit and continue exercise through the completion of post-operative chemotherapy. Participants will work with an exercise professional with expertise working with oncology patients.
A risk-adjusted assessment of a target facility's quality measures (e.g. mortality rate, length of stay, readmission rate, complications rate, etc.) is determined with respect to the quality measures of a broader population base. Patient cohorts are identified corresponding to particular ailments or treatments, and the target facility's risk-adjusted quality measures are determined for each cohort. When a particular quality measure for a target cohort indicates poor performance, factors that are determined to be relevant to the patients' outcomes are identified and used to create a control group of patients in the broader population who exhibit similar factors but had better outcomes than the patients of the target cohort. The care process (treatments, medications, interventions, etc.) that each of the target patients received is compared to the care process that each of the control patients received, to identify potential root-causes of the poorer performance.
In 18-month or 2-year dietary carcinogenicity studies in mice or rats, respectively, epinastine was not carcinogenic at doses up to 40 mg/kg [approximately 30,000 times higher than the MROHD, assuming 100% absorption in humans and animals].

Epinastine in newly synthesized batches was negative for mutagenicity in the Ames / Salmonella assay and in vitro chromosome aberration assay using human lymphocytes. Positive results were seen with early batches of epinastine in two in vitro chromosomal aberration studies conducted in the 1980s with human peripheral lymphocytes and with V79 cells, respectively. Epinastine was negative in the in vivo clastogenicity studies, including the mouse micronucleus assay and chromosome aberration assay in Chinese hamsters. Epinastine was also negative in the cell transformation assay using Syrian hamster embryo cells, V79/HGPRT mammalian cell point mutation assay, and in vivo/in vitro unscheduled DNA synthesis assay using rat primary hepatocytes.

Epinastine had no effect on fertility of male rats. Decreased fertility in female rats was observed at an oral dose up to approximately 90,000 times the MROHD.
The freeze-dried virus-stabiliser prod is heated at 50-150 degress C esp. 90-125 degrees C for 5-35 mins, pspec. 100 degrees C for 20, mins. Stabilisers are suitably heat- or acid-degraded gelatine, opt. contg. sorbitol or a compsn contg albumin, sugar phosphate and glutamine and are used at 1 mu g-30mg per haemagglutination unit. Viruses are esp. adeno- or myxoviruses esp. Sendai virus strain M34996, measles virus Edmonton strain, influenza strain WRL 55 or infectious canine hepatitis virus. The process leaves the nanogranular layer of the myxovirus intact and vaccines have better storage stability than those produced by chemical inactivation of the virus.